Evaluation of radiolabeled (Hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma

Journal of Medicinal Chemistry

Volumn 51, Issue 11, 2008, Pages 3133-3144

  Chezal, Jean Michel ^a   Papon, Janine ^a   Labarre, Pierre ^a   Lartigue, Claire ^a   Galmier, Marie Josephe ^a   Decombat, Caroline ^a   Chavignon, Olivier ^a   Maublant, Jean ^a   Teulade, Jean Claude ^a   Madelmont, Jean Claude ^a   Moins, Nicole ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC COMPOUND; BENZAMIDE DERIVATIVE; IODINE 125; N (2 DIETHYLAMINOETHYL) 4 IODOBENZAMIDE DERIVATIVE; N (2 DIETHYLAMINOETHYL) 6 IODOQUINOLINE 2 CARBOXAMIDE I 125; N (2 DIETHYLAMINOETHYL) 6 IODOQUINOXALINE 2 CARBOXAMIDE I 125; RADIOACTIVE IODINE; RADIOISOTOPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SYNTHESIS; DRUG TUMOR LEVEL; ISOTOPE LABELING; MALE; MELANOMA; MORBIDITY; MOUSE; NONHUMAN; RADIATION DOSE DISTRIBUTION; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

ANIMALS; BENZAMIDES; IODINE RADIOISOTOPES; MALE; MELANINS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; QUINOLINES; QUINOXALINES; RADIOPHARMACEUTICALS; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 44949103190     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701424g     Document Type: Article

References (52)

1. Thompson, J. F.; Scolyer, R. A.; Kefford, R. F. Cutaneous melanoma. Lancet 2005, 365, 687-701.
2. Balch, C. M.; Soong, S. J.; Gershenwald, J. E.; Thompson, J. F.; Reintgen, D. S.; Cascinelli, N.; Urist, M.; McMasters, K. M.; Ross, M. I.; Kirkwood, J. M.; Atkins, M. B.; Thompson, J. A.; Coit, D. G.; Byrd, D.; Desmond, R.; Zhang, Y.; Liu, P. Y.; Lyman, G. H.; Morabito, A. Prognostic Factors Analysis of 17600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. J. Clin. Oncol. 2001, 19, 3622-3634.
3. Middleton, M. R.; Grob, J. J.; Aaronson, N.; Fierlbeck, G.; Tilgen, W.; Seiter, S.; Gore, M.; Aamdal, S.; Cebon, J.; Coates, A.; Dreno, B.; Henz, M.; Schadendorf, D.; Kapp, A.; Weiss, J.; Fraass, U.; Statkevich, P.; Muller, M.; Thatcher, N. Randomized phase III study of Temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 2000, 18, 158-166.
4. Hauschild, A.; Garbe, C.; Stolz, W.; Ellwanger, U.; Seiter, S.; Dummer, R.; Ugurel, S.; Sebastian, G.; Nashan, D.; Linse, R.; Achtelik, W.; Mohr, P.; Kaufmann, R.; Fey, M.; Ulrch, J.; Tilgen, W. Dacarbazine and interferon alpha with or whihout interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (deCOG). Br. J. Cancer 2001, 84, 1036-1042.
5. Eigentler, T. K.; Caroli, U.; Radny, P.; Garbe, C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol. 2003, 4, 748-759.
6. Garbe, C.; Eigentler, T. K. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 2007, 17, 117-127.
7. Tsao, H.; Atkins, M. B.; Sober, A. J. Management of cutaneous melanoma. N. Engl. J. Med 2004, 351, 998-1012.
8. 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J. Nucl. Med. 2007, 48, 73-80.
9. 188Re-labeled α-Melanocyte- Stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J. Nucl. Med. 2005, 46, 121-129.
10. Miao, Y.; Hylarides, M.; Fisher, D. R.; Shelton, T.; Moore, H.; Wester, D. W.; Fritzberg, A. R.; Winkelmann, C. T.; Hoffman, T.; Quinn, T. P. Melanoma therapy via peptide-targeted (alpha)-radiation. Clin. Cancer Res. 2005, 11, 5616-5621.
11. 208Pb, yielding an α-particle and several β and γ emissions.
12. (a) Jimbow, K.; Miyake, Y.; Homma, K.; Yasuda, K.; Izumi, Y.; Tsutsumi, A.; Ito, S. Characterization of melanogenesis, and morphogenesis of melanosomes by physiochemical properties of melanin and melanosomes in malignant melanoma. Cancer Res. 1984, 44, 1128-1134.
13. (b) Hunt, G.; Kyne, S.; Ito, S.; Wakamatsu, K.; Todd, C.; Thody, A. Eumelanin and phaeomelanin contents of human epidermis and cultured melanocytes. Pigment Cell Res. 1995, 8, 202-208.
14. (c) Ancans, J.; Tobin, D. J.; Hoogduijn, M. J.; Smit, N. P.; Wakamatsu, K.; Thody, A. J. Melanosomal pH controls of melanogenesis, eumelanin/ phaeomelanin ratio and melanosome maturation in melanocytes and melanoma cells. Exp. Cell Res. 2001, 268, 26-35.
15. Prota, G. Melanins, melanogenesis and melanocytes: looking at their functional significance from the chemist's viewpoint. Pigment Cell Res. 2000, 13, 283-293.
16. Deibel, R. M. B.; Chedekel, M. R. Biosynthetic and structural studies on Pheomelanin. 2. J. Am. Chem. Soc. 1984, 106, 5884-5888.
17. Ings, R. M. The melanin binding of drugs and its implications. Drug Metab. Rev. 1984, 15, 1183-1212.
18. Link, E. M.; Lukiewicz, S. A new radioactive drug selectively accumulating in melanoma cells. Eur. J. Nucl. Med. 1982, 7, 469-473.
19. Link, E. M.; Blower, P. J.; Costa, D. C.; Lane, D M.; Lui, D.; Brown, R. S. D.; Ell, P. J.; Spittle, M. F. Early detection of melanoma metastases with radioiodinated methylene blue. Eur. J. Nucl. Med. 1998, 25, 1322-1329.
20. 211At-Methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of cutaneous tumours and lymph node metastases. Cancer Res. 1992, 52, 4385-4390.
21. Kassis, A. I.; Adelstein, S. J. Radiobiologic principles in radionuclide therapy. J. Nucl. Med. 2005, 46, 4S-12S
22. (a) Michelot, J. M.; Moreau, M. F. C.; Veyre, A. J.; Bonafous, J. F.; Bacin, F. J.; Madelmont, J. C.; Bussiere, F.; Souteyrand, P. A.; Mauclaire, L. P.; Chossat, F. M.; Papon, J. M.; Labarre, P. G.; Kauffmann, Ph.; Plagne, R. J. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide). J. Nucl. Med. 1993, 34, 1260-1266.
23. 123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging. Eur. J. Nucl. Med. 2002, 29, 1478-1484.
24. (a) Chehade, F.; De Labriolle-Vaylet, C.; Michelot, J.; Moins, N.; Moreau, M. F.; Hindie, E.; Papon, J.; Escaig, F.; Galle, P.; Veyre, A. Distribution of I-BZA (N-2-diethylaminoethyl-4-iodobenzamide) in grafted melanoma and normal skin: A study by secondary ion mass spectroscopy. Cell. Mol. Biol. 2001, 47, 529-534.
25. (b) Guerquin-Kern, J. L.; Hillion, F.; Madelmont, J. C.; Labarre, P.; Papon, J.; Croisy, A. Ultra-structural cell distribution of the melanoma marker iodobenzamide: improved potentiality of SIMS imaging in life sciences. Biomed. Eng. Online 2004, 3, 10.
26. Labarre, P.; Papon, J.; Moreau, M. F.; Moins, N.; Bayle, M.; Veyre, A.; Madelmont, J. C. Melanin affinity of N-(2-diethylaminoethyl)-4- iodobenzamide, an effective melanoma imaging agent. Melanoma Res. 2002, 12, 115-121.
27. Moreau, M. F.; Papon, J.; Labarre, P.; Moins, N.; Borel, M.; Bayle, M.; Bouchon, B.; Madelmont, J. C. Synthesis, in vitro-binding and biodistribution in B16 melanoma-bearing mice of new iodine-125 spermidine benzamide derivatives. Nucl. Med. Biol. 2005, 32, 377-384.
28. Pham, T. Q.; Greguric, I.; Liu, X.; Berghofer, P.; Ballantyne, P.; Chapman, J.; Mattner, F.; Dikic, B.; Jackson, T.; Loc'h, C.; Katsifis, A. Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma. J. Med. Chem. 2007, 50, 3561-3572.
29. Moins, N.; Papon, J.; Seguin, H.; Gardette, D.; Moreau, M. F.; Labarre, P.; Bayle, M.; Michelot, J.; Gramain, J. C.; Madelmont, J. C.; Veyre, A. Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents. Nucl. Med. Biol. 2001, 28, 799-808.
30. Eisenhut, M.; Hull, W. E.; Mohammed, A.; Mier, W.; Lay, D.; Just, W.; Gorgas, K.; Lehmann, W. D.; Haberkorn, U. Radioiodinated N-(2- diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization. J. Med. Chem. 2000, 43, 3913-3922.
31. Adcock, W.; Wells, P. R. Substituent effects in naphthalene. I. The syntheses of 4-, 5-, 6-, 7-, and 8-substituted 2-naphthoic acids. Aust. J. Chem. 1965, 18, 1351-1364.
32. Beshore, D. C.; Dinsmore, C. J. Preparation of ethyl 5-iodo-1H-indole-2-carboxylate. Synth. Commun. 2003, 33, 2423-2427.
33. Bridges, A. J.; Lee, A.; Maduakor, E. C.; Schwartz, C. E. Fluorine as an ortho-directing group in aromatic metalation: A two step preparation of substituted benzo[b]thiophene-2-carboxylates. Tetrahedron Lett. 1992, 33, 7499-7502.
34. Sunberg, R. J.; Biswas, S.; Murthi, K. K.; Rowe, D.; McCall, J. W.; Dzimianski, M. T. Bis-cationic heteroaromatics as macrofilaricides: synthesis of bis-amidine and bis-guanylhydrazone derivatives of substituted imidazo[1,2-a]pyridines. J. Med. Chem. 1998, 41, 4317-4328.
35. Lin, A. J.; Loo, T. L. Synthesis and antitumour activity of halogen-substituted 4-(3,3-dimethyl-1-triazeno)quinolines. J. Med. Chem. 1978, 21, 268-272.
36. Newkome, G. R.; Moorfield; C. N.; Sabbaghian, B. Chemistry of heterocyclic compounds series. Part 108. Reductive dehalogenation of electron-poor heterocycles: nicotinic acid derivatives. J. Org. Chem. 1986, 51, 953-954.
37. Kim, S.; Lee, J. I.; Kim, Y. C. A simple and mild esterification method for carboxylic acids using mixed carboxylic-carbonic anhydrides. J. Org. Chem. 1985, 50, 560-565.
38. Buchel, K. H. Synthesen von elektronegativ substituierten benzimidazolen. Z. Naturforsch., B 1970, 25, 945-953.
39. Rabiger, D. J.; Joullié, M. M. Preparation of 5(6)- iodobenzimidazole and 4(7)-iodobenzimidazole. J. Org. Chem. 1961, 26, 1649-1650.
40. 1A receptor agonists and serotonin reuptake inhibitors. J. Med. Chem. 2004, 47, 4684-4692.
41. Baraldi, P. G.; Romagnoli, R.; Beria, I.; Cozzi, P.; Geroni, C.; Mongelli, N.; Bianchi, N.; Mischiati, C.; Gambari, R. Synthesis and antitumor activity of new benzoheterocyclic derivatives of distamycin A. J. Med. Chem. 2000, 43, 2675-2684.
42. Bachman, G. B.; Micucci, D. D. Monomer and polymers. V. Vinylpyridines and Vinylquinolines. J. Am. Chem. Soc. 1948, 70, 2381-2384.
43. Petrow, V.; Sturgeon, B. Some quinoline-5.8-quinones. J. Chem. Soc. 1954, 570-574.
44. Lee, C. H.; Bayburt, E. K.; DiDomenico, S.; Drizin, I.; Gomtsyan, A. R.; Koenig, J. R.; Perner, R. J.; Schmidt, R. G.; Turner, S. C.; White, T. K.; Zheng, G. Z. Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor. U.S. Patent, 2003158188, 2003.
45. Higashida, S.; Sakurai, M.; Yabe, Y.; Nishihgaki, T.; Komai, T.; Handa, H. Preparation of peptide inhibitors of HIV protease. Peptides capable of inhibiting the activity of HIV protease, their preparation and their therapeutic use. European Patent, EP0587311, 1994.
46. Chan, L.; Jin, H.; Stefanac, T.; Lavallée, J. F.; Falardeau, G.; Wang, W.; Bédard, J.; May, S.; Yuen, L. Discovery of 1,6-naphthyridines as a novel class of potent and selective human cytomegalovirus inhibitors. J. Med. Chem. 1999, 42, 3023-3025.
47. Michelot, J. M.; Moreau, M. F. C.; Labarre, P. G.; Madelmont, J. C.; Veyre, A. J.; Papon, J. M.; Parry, D. F.; Bonafous, J. F.; Boire, J. Y. P.; Desplanches, G. G.; Bertrand, S. J.; Meyniel, G. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. J. Nucl. Med. 1991, 32, 1573-1580.
48. Kassis, A.I.; Adelstein, S. J. Radiobiologic principles in radionuclide therapy. J. Nucl. Med. 2005, 46, 4S-12S
49. Armarego, W. L. F.; Petrin, D. D. Purification of laboratory chemicals, 4th ed.; - Eds.; Butterworth- Heinemann: Oxford, UK, 1996.
50. Labarre, P.; Papon, J.; Moreau, M. F.; Moins, N.; Veyre, A.; Madelmont, J. C. Evaluation in mice of some iodinated melanoma imaging agents using cryosectioning and multiwire proportional counting. Eur. J. Nucl. Med. 1999, 26, 494-498.
51. Gillett, S. J.; Garst, M. E.; Johnson, A. T. Method for preparing esters of halonicotinic acids. World Patent, WO9612701, 1996.
52. Labarre, P.; Papon, J.; Moreau, M. F.; Madelmont, J. C.; Veyre, A. A new quantitative method to evaluate the biodistribution of a radiolabeled tracer for melanoma using whole-body cryosectioning and a gaseous detector. Comparison with conventional tissue combustion technology. Eur. J. Nucl. Med. 1998, 25, 109-114.